Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pan-Provincial Vaccine Enterprise
Saskatoon, Saskatchewan, Canadaprevent-cecr.ca ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PREVENT accelerated Canadian early-stage vaccine candidates to animal studies and proof-of-concept trials, with some projects advancing to human clinical testing; notable for collaboration on a multivalent group A streptococcus vaccine with Vaxent
- Therapeutic areas
- Infectious DiseasesRheumatologyCardiovascular
- Modalities
- VaccineProtein (specifically recombinant protein subunit vaccines)
- Industry
- Academic Hospital/University/Research
02
Partnerships
Vaxent (co-development of Group A Streptococcus vaccine)Vaccine and Infectious Disease Organization (VIDO/University of Saskatchewan)BC Centre for Disease Control (BC-CDC)Canadian Center for Vaccinology (CCfV)
Beyond the preview
Go deeper on Pan-Provincial Vaccine Enterprise.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pan-Provincial Vaccine Enterprise.